PADCEV (Astellas Pharma US, Inc. / Pfizer Inc.)
(https://padcev.com) 📸 Data Snapshot: May 31, 2026
Identity & Authority — The Lens
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Identity & Authority
Expert verifiability & Schema depth.
15
Impact Weight: 15 / 100
100% Reputation
Authority is well-established through robust schema.json that identifies the manufacturers (Astellas and Pfizer) and the specific medical specialty (Oncologic). The site mentions a specific expert, Dr. Putao Cen, within the VideoObject schema, though there is a minor gap as there is no Person schema with sameAs links to verify the oncologist’s professional footprint directly on the page.
There is no disconnect between marketing tone and demonstrated facts. Performance claims are limited to clinical trial data (e.g., survival months and patient counts) which are presented alongside mandatory safety warnings. The tone is informative and risk-aware rather than promotional.
Identity & Authority is read from the structured data first: whether the site declares who it is in machine-readable schema, with verifiable identity links. Below is the schema captured per page, then the external proof links that support (or fail to support) that identity.
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps
Homepage schema
{
"@context": "http://schema.org/",
"@type": "MedicalWebPage",
"specialty": "https://health-lifesci.schema.org/Oncologic",
"audience": "https://health-lifesci.schema.org/Patient",
"url": "https://www.padcev.com/",
"name": "Home",
"headline": "PADCEV® (enfortumab vedotin-ejfv) for Advanced Bladder Cancer",
"description": "PADCEV is used to treat advanced bladder cancer and can be used alone or together with pembrolizumab (also known as Keytruda®). See full Prescribing Information, including Serious Side Effects.",
"potentialAction": [
{
"@type": "ViewAction",
"name": "How PADCEV May Help",
"description": "People who were treated only with PADCEV® demonstrated a median overall survival of 13 months versus 9 months with chemotherapy. This was based on a study of 608 adults with advanced bladder cancer who previously received immunotherapy medicine and cisplatin- or carboplatin-containing chemotherapy.",
"url": "https://www.padcev.com/trial-results"
},
{
"@type": "ViewAction",
"name": "How PADCEV with pembrolizumab may help as a first treatment for advanced bladder cancer",
"description": "PADCEV with pembrolizumab For people who have not yet received a treatment for advanced bladder cancer",
"url": "https://www.padcev.com/trial-results"
},
{
"@type": "ViewAction",
"name": "How PADCEV may help after previous treatment for advanced bladder cancer",
"description": "PADCEV alone For people who have previously received an immunotherapy medicine and chemotherapy that contains platinum (cisplatin or carboplatin) Or For people who are unable to receive cisplatin containing chemotherapy and were previously treated with one or more prior therapies",
"url": "https://www.padcev.com/trial-results"
},
{
"@type": "ViewAction",
"name": "View More Patient Stories",
"url": "https://www.padcev.com/real-patient-stories"
},
{
"@type": "ViewAction",
"name": "PADCEV Support Solutions℠ can help provide you or your loved one with information about financial assistance programs.",
"url": "https://www.padcev.com/padcev-support-solutions"
},
{
"@type": "DownloadAction",
"name": "Download the PADCEV Discussion Guide & Symptom Tracker to help start a conversation with your doctor.",
"url": "https://www.padcev.com/Content/pdf/PADCEV-DDG_Symptom_Tracker.pdf"
},
{
"@type": "ViewAction",
"name": "About Advanced Bladder Cancer",
"url": "https://www.padcev.com/about-advanced-bladder-cancer"
},
{
"@type": "ViewAction",
"name": "Downloads and Links",
"url": "https://www.padcev.com/resources"
},
{
"@type": "ViewAction",
"name": "Frequently Asked Questions",
"url": "https://www.padcev.com/frequently-asked-questions"
}
],
"video": {
"@type": "VideoObject",
"name": "Bodiul's path to PADCEV",
"description": "Bodiul and his oncologist, Dr Putao Cen, talk about his journey with advanced bladder cancer and his experience being treated with PADCEV.",
"thumbnailUrl": "https://www.padcev.com/Content/images/Bodiul-placeholder-v2.png",
"uploadDate": "2022-12-14",
"duration": "PT11M13S",
"embedUrl": "https://app.frame.io/presentations/5dd01843-1d77-44fb-ae93-1cc7537d6ed9"
},
"about": [
{
"@type": "Drug",
"name": "PADCEV",
"alternateName": "enfortumab vedotin-ejfv",
"description": "PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used with pembrolizumab (also known as Keytruda®), or PADCEV may be used alone if you: have received an immunotherapy medicine and chemotherapy that contains platinum, or are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy. It is not known if PADCEV is safe and effective in children.",
"image": {
"@type": "ImageObject",
"name": "PADCEV (enfortumab vedotin-ejfv) logo",
"contentUrl": "https://www.padcev.com/Content/images/Nav-icons/Padcev-Nav-Logo.svg"
},
"offers": {
"@type": "Offer",
"name": "PADCEV Support Solutions℠",
"description": "PADCEV Support Solutions offers information to help you understand your insurance coverage for PADCEV®. PADCEV Support Solutions will provide your healthcare professional with a summary of your insurance benefits. We can also help determine if your insurer requires a prior authorization (PA). If your insurer denies a PA request, and your healthcare professional determines that an appeal is appropriate, PADCEV Support Solutions can assist with the appeal.",
"price": "0",
"priceCurrency": "USD"
},
"prescribingInfo": "https://astellas.us/docs/PADCEV_label.pdf",
"manufacturer": {
"@type": "Organization",
"name": "Astellas",
"logo": "https://www.padcev.com/Content/images/Astellas_Oncology_Logo.png",
"url": "https://www.astellas.com/us/"
}
},
{
"@type": "MedicalCondition",
"name": [
"bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery"
]
}
]
}
/contact/
{
"@context": "http://schema.org/",
"@type": "MedicalWebPage",
"specialty": "https://health-lifesci.schema.org/Oncologic",
"audience": "https://health-lifesci.schema.org/Patient",
"url": "https://www.padcev.com/contact",
"name": "Contact",
"headline": "Contact Us: PADCEV® (enfortumab vedotin-ejfv)",
"description": "Find contact information for PADCEV® (enfortumab vedotin-ejfv). Call 1-888-4PADCEV.",
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": "1",
"name": "Home",
"item": "https://www.padcev.com/"
},
{
"@type": "ListItem",
"position": "2",
"name": "Contact",
"item": "https://www.padcev.com/contact"
}
]
},
"potentialAction": [
{
"@type": "ViewAction",
"name": "Astellas Pharma US, Inc. Website",
"url": "https://www.astellas.com/us/"
},
{
"@type": "ViewAction",
"name": "Seagen Inc. Website",
"url": "https://www.seagen.com/"
}
],
"about": [
{
"@type": "Drug",
"name": "PADCEV",
"alternateName": "enfortumab vedotin-ejfv",
"description": "PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used with pembrolizumab (also known as Keytruda®), or PADCEV may be used alone if you: have received an immunotherapy medicine and chemotherapy that contains platinum, or are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy. It is not known if PADCEV is safe and effective in children.",
"dosageForm": "intravenous infusion",
"prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
"image": {
"@type": "ImageObject",
"name": "PADCEV (enfortumab vedotin-ejfv) logo",
"contentUrl": "https://www.padcev.com/Content/images/PADCEV-(enfortumab-vedotin-ejfv).svg"
},
"offers": {
"@type": "Offer",
"name": "PADCEV Support Solutions℠",
"description": "PADCEV Support Solutions offers information to help you understand your insurance coverage for PADCEV®. PADCEV Support Solutions will provide your healthcare professional with a summary of your insurance benefits. We can also help determine if your insurer requires a prior authorization (PA). If your insurer denies a PA request, and your healthcare professional determines that an appeal is appropriate, PADCEV Support Solutions can assist with the appeal.",
"price": "0",
"priceCurrency": "USD"
},
"prescribingInfo": "https://astellas.us/docs/PADCEV_label.pdf",
"manufacturer": {
"@type": "Organization",
"name": "Astellas",
"logo": "https://www.padcev.com/Content/images/Astellas_Oncology_Logo.png",
"url": "https://www.astellas.com/us/"
}
},
{
"@type": "MedicalCondition",
"name": [
"bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery"
]
}
]
}
/terms-of-use/
{
"@context": "http://schema.org/",
"@type": "MedicalWebPage",
"specialty": "https://health-lifesci.schema.org/Oncologic",
"audience": "https://health-lifesci.schema.org/Patient",
"url": "https://www.padcev.com/terms-of-use",
"name": "Terms of Use",
"headline": "Terms of Use: PADCEV® (enfortumab vedotin-ejfv) Website",
"description": "See the Terms of Use for the PADCEV website.",
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": "1",
"name": "Home",
"item": "https://www.padcev.com/"
},
{
"@type": "ListItem",
"position": "2",
"name": "Terms of Use",
"item": "https://www.padcev.com/terms-of-use"
}
]
},
"about": {
"@type": "Organization",
"name": "Astellas",
"logo": "https://www.padcev.com/Content/images/Astellas_Oncology_Logo.png",
"url": "https://www.astellas.com/us/"
}
}
/site-map/
{
"@context": "http://schema.org/",
"@type": "MedicalWebPage",
"specialty": "https://health-lifesci.schema.org/Oncologic",
"audience": "https://health-lifesci.schema.org/Patient",
"url": "https://www.padcev.com/site-map",
"name": "Site Map",
"headline": "Site Map: PADCEV® (enfortumab vedotin-ejfv)",
"description": "See the site map for the PADCEV website.",
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": "1",
"name": "Home",
"item": "https://www.padcev.com/"
},
{
"@type": "ListItem",
"position": "2",
"name": "Site Map",
"item": "https://www.padcev.com/site-map"
}
]
},
"relatedLink": [
"https://www.padcev.com/",
"https://www.padcev.com/about-advanced-bladder-cancer",
"https://www.padcev.com/about-padcev",
"https://www.padcev.com/dosing-administration",
"https://www.padcev.com/trial-results",
"https://www.padcev.com/side-effects",
"https://www.padcev.com/caregiver-tips",
"https://www.padcev.com/resources",
"https://www.padcev.com/frequently-asked-questions",
"https://www.padcev.com/padcev-support-solutions",
"https://www.padcev.com/real-patient-stories",
"https://www.padcev.com/hcp",
"https://www.padcev.com/contact",
"https://www.padcev.com/site-map",
"https://www.padcev.com/terms-of-use"
],
"about": {
"@type": "Organization",
"name": "Astellas",
"logo": "https://www.padcev.com/Content/images/Astellas_Oncology_Logo.png",
"url": "https://www.astellas.com/us/"
}
}
🛡️ Trust Signals — external proof links that back the declared identity
5Review mentions (all pages)
0External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 1 | 0 |
| /contact/ | 1 | 0 |
| /terms-of-use/ | 2 | 0 |
| /site-map/ | 1 | 0 |
Explore the other reputation pillars for PADCEV (Astellas Pharma US, Inc. / Pfizer Inc.)
Analysis Disclosure & Source Attribution
This page presents a snapshot of public data from PADCEV (Astellas Pharma US, Inc. / Pfizer Inc.), captured on May 31, 2026, to show how machine logic reads Identity & Authority signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to PADCEV (Astellas Pharma US, Inc. / Pfizer Inc.): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://padcev.com to view the most current version of its content and see directly what this company is about and what it offers.